180 Life Sciences Corp. (NASDAQ:ATNF) Sees Significant Decrease in Short Interest

180 Life Sciences Corp. (NASDAQ:ATNF) was the recipient of a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 17,100 shares, a drop of 59.7% from the March 31st total of 42,400 shares. Approximately 3.3% of the company’s shares are short sold. Based on an average daily volume of 103,100 shares, the short-interest ratio is currently 0.2 days.

180 Life Sciences Trading Down 2.8 %

Shares of ATNF traded down $0.05 during midday trading on Thursday, hitting $1.77. 15,531 shares of the stock were exchanged, compared to its average volume of 106,529. 180 Life Sciences has a 52-week low of $1.33 and a 52-week high of $27.93. The stock has a fifty day simple moving average of $2.86 and a 200 day simple moving average of $4.69.

Hedge Funds Weigh In On 180 Life Sciences

An institutional investor recently bought a new position in 180 Life Sciences stock. Armistice Capital LLC acquired a new stake in 180 Life Sciences Corp. (NASDAQ:ATNF) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 131,000 shares of the company’s stock, valued at approximately $80,000. Armistice Capital LLC owned 2.46% of 180 Life Sciences as of its most recent filing with the Securities and Exchange Commission (SEC). 4.07% of the stock is owned by institutional investors and hedge funds.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.